Clinical trials: Lymphoma, B-Cell Refractory
Primary CNS Lymphoma (PCNSL)
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
The purpose of this phase 2 study is to evaluate the efficacy and safety of epcoritamab in subjects with relapsed or refractory primary diffuse large B-cell lymphoma of the Central Nervous System treated with rituximab and…
- Trial name
- E-REVRI (NCT06931652)
- Testing
- Epcoritamab
- Where
- 13 sites in France
- Volunteers
- 60 people
- Sponsor
- The Lymphoma Academic Research Organisation
Acute Lymphoblastic Leukemia
CAV Regimen for R/R Ph- B-ALL
This study aims to investigate the efficacy and safety of cladribine, venetoclax combined with cytarabine and venetoclax (CAV regimen) for relapsed/refractory (R/R) Philadelphia Chromosome-negative (Ph-) B-cell acute…
- Trial name
- NCT05657652
- Testing
- cladribine, cytarabine,venetoclax
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital of Soochow University
B-cell Malignancy
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).
- Trial name
- NCT05106907
- Testing
- ThisCART19 cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fundamenta Therapeutics, Ltd.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SHC014748M in patients with relapsed or refractory indolent B-cell hematologic malignancies.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), B-Cell Non-Hodgkin Lymphomas(NHL)
- Trial name
- NCT03588598
- Testing
- SHC014748M
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
B-cell Lymphomas
Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)
The investigators are willing to investigate the efficacy and safety of oxaliplatin and prednisolone (Ox-P) combination in patients with previously treated MZL who have a few clinical trial data.
- Trial name
- NCT01068392
- Testing
- Oxaliplatin, Prednisolone
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Dong-A University Hospital
Cancer, Neoplasms
A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment
The Purpose of this study is to evaluate the safety and tolerability, and the biological effects of the chimeric anti-CD40 monoclonal antibody Chi Lob 7/4, given intravenously, weekly for 4 weeks in the treatment of patients with…
- Conditions
- Cancer, Neoplasms, Lymphoma, Non-Hodgkin
- Trial name
- NCT01561911
- Testing
- Chi Lob 7/4 (A chimeric monoclonal antibody)
- Where
- 2 sites in United Kingdom
- Volunteers
- 29 people
- Sponsor
- Cancer Research UK
Leukemia, B-Cell
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
The purpose of the study is to determine the maximum tolerated dose (MTD) in patients with acute lymphoblastic leukemia (ALL) and to determine the safety and tolerability of increasing doses and different infusion times of AFM11…
- Trial name
- NCT02848911
- Testing
- AFM11
- Where
- 12 sites in Austria, Czechia and 3 more
- Volunteers
- 17 people
- Sponsor
- Affimed GmbH
Relapsed or Refractory Diffuse Large B-cell Lymphoma
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
This is an open,single-arm,multicenter phase II clinical study to evaluate the efficacy and safety of BEBT-908 for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT06074107
- Testing
- BEBT-908 for injection
- Where
- China
- Volunteers
- 128 people
- Sponsor
- BeBetter Med Inc
Relapsed Non Hodgkin Lymphoma, Refractory Lymphoma
Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma
This study enrolled patients with relapsed or refractory diffuse large B cell lymphoma treated with polatuzumab vedotin-based chemoimmunotherapies.
- Trial name
- NCT05006534
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
This phase I trial studies the side effects and the best dose of everolimus when given together with bendamustine hydrochloride in treating patients with cancer of the blood (hematologic cancer) that has returned after a period…
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT02240719
- Testing
- everolimus, bendamustine hydrochloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Davis
Non-Hodgkin's B-cell Lymphoma
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B-NHL patients.
- Trial name
- NCT04696432
- Testing
- Prizloncabtagene autoleucel
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Chronic Myeloproliferative Disorders
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003107
- Testing
- recombinant interleukin-12
- Where
- United States
- Sponsor
- Indiana University
Lymphoma
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with rituximab in subjects with refractory or relapsed CD20+…
- Trial name
- NCT03189836
- Testing
- ACTR707, rituximab
- Where
- 11 sites in United States
- Volunteers
- 26 people
- Sponsor
- Cogent Biosciences, Inc.
Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
This phase II trial studies how well carfilzomib with or without rituximab work in treating patients with Waldenstrom macroglobulinemia or marginal zone lymphoma that is previously untreated, has come back, or does not respond to…
- Conditions
- Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma
- Trial name
- NCT03269552
- Testing
- Carfilzomib, Laboratory Biomarker Analysis, Rituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Washington
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as flavopiridol, work in different ways to stop cancer cells from dividing so they stop growing…
- Conditions
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma
- Trial name
- NCT00082784
- Testing
- Bortezomib, Alvocidib Hydrochloride, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Fever, Sweats, and Hot Flashes, Infection
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00020865
- Testing
- cefepime hydrochloride, levofloxacin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Chronic Lymphocytic Leukemia (CLL)
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Investigational Drugs: Ofatumumab (Azerra) + bendamustine (Trenda) Route of Administration: Intravenous (IV) Hypothesis: This study is designed to assess the toxicity and overall response rate.
- Trial name
- NCT01131247
- Testing
- ofatumumab + bendamustine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Nevada Cancer Institute
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab)…
- Trial name
- CaDAnCe-303 (NCT06970743)
- Testing
- BGB-16673, Bendamustine, Rituximab
- Where
- 56 sites in China, Taiwan
- Volunteers
- 153 people
- Sponsor
- BeOne Medicines
Cancer
Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer
RATIONALE: Telephone counseling by trained counselors may enhance the well-being and quality of life of patients who have undergone stem cell transplantation for cancer.
- Trial name
- NCT00049465
- Testing
- fatigue assessment and management, management of therapy complications, psychosocial assessment and care
- Where
- 9 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL)
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed/refractory B-cell…
- Conditions
- Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
- Trial name
- NCT07077512
- Testing
- Autoleucel (Relmacabtagene Autoleucel), Sintilimab (PD-1 inhibitor)
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.